---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122814"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:48:39.243613+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics reports Q3 net loss $46.6M, raises $345M; atacicept Ph3 enrollment done

## Summary
- Net loss of $46.6M ($0.85/shr) vs $20.1M ($0.45) in Q3 2023; cash $353.3M as of Sept 30.
- Completed $345M public equity offering to fund atacicept launch and regulatory submission.
- Phase 3 ORIGIN 3 trial enrollment complete; topline data expected in Q2 2025.
- Positive 96-week eGFR stabilization data from Phase 2 ORIGIN trial at ASN Kidney Week 2024.
- Expanded atacicept development with PIONEER trial in broader IgAN and other kidney diseases.

## SEC filing metadata
- accession: 0000950170-24-122814
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000095017024122814/0000950170-24-122814-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000095017024122814/vera-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122814
- JSON: https://secwatch.observer/filing/0000950170-24-122814.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122814.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.